AstraZeneca ( AstraZeneca)

Primary tabs

AstraZeneca's picture

Management

Contact Address

About AstraZeneca

AstraZeneca plc is a British–Swedish multinational pharmaceutical and biopharmaceutical company. In 2013 it moved its headquarters to Cambridge, England, and concentrated its R&D in three sites: Cambridge, Gaithersburg, Maryland (location of MedImmune) for work on biopharmaceuticals, and Mölndal (near Gothenburg) in Sweden, for research on traditional chemical drugs. In 2015 it was the eighth largest drug company in the world based on sales revenue.

AstraZeneca press release, blog etc

Fri, 04/29/2022 - 04:09 AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts
Thu, 02/17/2022 - 06:11 Nirsevimab EMA regulatory submission accepted under accelerated assessment for RSV protection in all infants
Mon, 01/17/2022 - 21:05 Imfinzi plus tremelimumab demonstrated unprecedented survival in 1st-line unresectable liver cancer with 31% of patients alive at three years
Thu, 01/13/2022 - 11:48 AstraZeneca and Scorpion Therapeutics enter agreement to discover, develop and commercialise novel cancer treatments against undruggable targets
Thu, 01/13/2022 - 11:17 AstraZeneca aims to redefine liver, biliary tract and prostate cancer treatment with practice-changing Imfinzi and Lynparza data at ASCO GI and GU
Fri, 01/07/2022 - 16:39 AstraZeneca and Neurimmune sign exclusive global collaboration and licence agreement to develop and commercialise NI006
Wed, 01/05/2022 - 03:24 Transfer of global rights for Eklira and Duaklir to Covis Pharma completed
Wed, 12/29/2021 - 15:33 AstraZeneca and Ionis close agreement to develop and commercialise eplontersen
Tue, 12/21/2021 - 06:21 Ultomiris regulatory submission accepted under FDA Priority Review in the US for adults with generalised myasthenia gravis
Thu, 12/09/2021 - 17:00 Enhertu additional analyses further reinforce ground-breaking efficacy in patients with HER2-positive metastatic breast cancer
Tue, 12/07/2021 - 13:17 AstraZeneca and Ionis sign deal to develop and commercialise eplontersen
Tue, 11/30/2021 - 20:33 Lynparza granted Priority Review in the US for BRCA-mutated HER2-negative high-risk early breast cancer
Tue, 11/16/2021 - 10:50 Two billion doses of AstraZenecas COVID-19 vaccine supplied to countries across the world less than 12 months after first approval
Mon, 11/01/2021 - 07:35 AstraZeneca to transfer global rights for Eklira and Duaklir to Covis Pharma
Fri, 10/08/2021 - 13:37 Tezepelumab granted Orphan Drug Designation in the US for eosinophilic esophagitis
Tue, 10/05/2021 - 06:32 AZD7442 request for Emergency Use Authorization for COVID-19 prophylaxis filed in US
Wed, 09/29/2021 - 03:15 AstraZeneca to fully acquire Caelum Biosciences
Thu, 09/23/2021 - 07:52 AstraZeneca to discover and develop self-amplifying RNA therapeutics in new collaboration with VaxEquity